Lausanne, Switzerland-based life sciences company, Lunaphore, raised CHF 40 million in the first close of its Series D funding. The round took place on March 23, 2023. Ernst-Göhner Stiftung Beteiligungen (EGSB) led the financing for the company. Meanwhile, existing investors PHC Holdings Corporation, Swiss Entrepreneurs Fund, OCCIDENT, and Redalpine participated. 

Out of the total funding, Norgine Ventures provided a debt facility of EUR 10 million. 

Purpose of financing for Lunaphore

With the latest proceeds from the Series D1 funding, the company seeks to strengthen its growing portfolio offering in spatial biology.

It also has plans to support commercial execution to address ever-growing demand from customers.

What the company’s official has to say

Ata Tuna Ciftlik, CEO of Lunaphore, said, “We are thrilled to have such a highly regarded name like EGSB among our investors. EGSB has an excellent track record of supporting rapidly growing portfolio companies beyond $100M in revenues. In addition, the debt facility from Norgine Ventures will help us to invest in scaling our company even faster. The funding comes in a meaningful time where we are experiencing excellent traction over the last 12 months since the first launch of our COMET™ product line. We are very proud to see the world’s best institutions and blue-chip pharma companies among our customers. The worlds leading research institutions use COMET™ and has been a growth driver for Lunaphore, where COMET™ sales grew more than 350% over 2022. The measured pull-through is best-in-class among existing comparables. We have proven again that there are endless possibilities provided by turning existing reagent libraries into spatial biology and that true end-to-end precision automation is highly needed in the market.”

What the investor has to add

Dominik Sauter, Managing Director of EGS Beteiligungen AG the investment, said, “Cutting edge technology enabling the next frontier in biology & medicine – that is Lunaphore. Lunaphore is at an inflexion point of its trajectory, and we are thrilled to support the leadership team around CEO Ata Tuna Ciftlik in executing their vision.”

About the company 

Ata Tuna Ciftlik, Diego Gabriel Dupouy, and Déborah Heintze launched the company in 2014. The Swiss life sciences company is developing technology to enable spatial biology in every laboratory. 

Lunaphore offers solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumours and other tissues. It further transforms any assay into multiplex spatial biology with an intuitive approach.

For more extensive analysis and Market Intelligence reports, feel free to approach us.

We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know

if there are any discrepancies in any of our published stories,

-how we can improve,

-what stories you would like us to cover

–what information you are looking for in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!

Next Article

Previous articleSingapore-based SaaS platform Mystifly raises USD 8 million in Pre-series B funding
Next articleBlockchain VC firm Contango Digital Assets raises USD 1.5 million in seed fundinga
Jasleen Bhatia works as a content writer for VCBay News. She is pursuing her final semester in Bachelor of Business Administration from IIPS, DAVV. Driven by her keen interest in entrepreneurship and finance, she writes business-related articles.


Please enter your comment!
Please enter your name here